SURMOUNT-1
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is SURMOUNT-1?
Tirzepatide at 5, 10 and 15 mg weekly against placebo, the pivotal phase 3, run across 2,539 participants carrying excess weight (Jastreboff et al., NEJM 2022, PMID 35658024).
The 15 mg arm averaged 20.9% loss across 72 weeks. That is the result that turned tirzepatide into a drug people request by name.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where SURMOUNT-1 comes up on this site
On GLP Watchdog, SURMOUNT-1 comes up in 5 research articles and 4 tools.
Research that discusses it
Tools that use it
Other terms under Major trials
Where the evidence lives
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers